Postprandial ultra-fast insulin versus mealtime fast-acting insulin in adults with cystic fibrosis-related diabetes: A randomized multicentre crossover trial.

Date publication

septembre 2026

Journal

Diabetes research and clinical practice

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MEYER Nicolas

Tous les auteurs :
Rakotoarisoa L, Mulette P, Chiron R, Ramel S, Ronsin O, Weiss L, Stremler N, Gabsi A, Mely L, Silva ID, Meyer N, Kessler L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42679861

Résumé

Postprandial administration of ultra-fast-acting insulin (PP-UFI) may offer greater flexibility for individuals with cystic fibrosis-related diabetes (CFRD). This study evaluated whether PP-UFI provides glycaemic control comparable to standard mealtime fast-acting insulin (MT-FI).

Mots clés

Cystic fibrosis–related diabetes, connected insulin pen, continuous glucose monitoring, post-meal insulin administration, ultra-fast-acting insulin

Référence

Diabetes Res Clin Pract. 2026 09 1;241:113544